[go: up one dir, main page]

CA2186847A1 - Derives adenosine - Google Patents

Derives adenosine

Info

Publication number
CA2186847A1
CA2186847A1 CA002186847A CA2186847A CA2186847A1 CA 2186847 A1 CA2186847 A1 CA 2186847A1 CA 002186847 A CA002186847 A CA 002186847A CA 2186847 A CA2186847 A CA 2186847A CA 2186847 A1 CA2186847 A1 CA 2186847A1
Authority
CA
Canada
Prior art keywords
compound
formula
alkyl
adenosine
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002186847A
Other languages
English (en)
Inventor
Fulvio Gadient
Bonnie L.K. Mangold
John R. Fozard
Mahavir Prashad
Prasad Koteswara Kapa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9409324A external-priority patent/GB9409324D0/en
Priority claimed from GB9416693A external-priority patent/GB9416693D0/en
Application filed by Individual filed Critical Individual
Publication of CA2186847A1 publication Critical patent/CA2186847A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Pain & Pain Management (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

Composés de la formule (I) dans laquelle R¿1? a plusieurs notations possibles, notamment cycloalkyle et hydroxycycloalkyle; R¿2? représente hydrogène, alkyle (C¿1-4?), amino, cycloalkyle (C¿3-5?) ou halogène d'un numéro atomique compris entre 9 et 35, et R¿3? représente alkyle (C¿1-4?). Ces composés sont utiles comme agents analgésiques. Les composés de la formule (I), dans laquelle R¿1? représente hydroxy-alkyle, sont nouveaux, et peuvent être produits par alkylation en position 2' en présence de sulfate d'hydrogène de tétrabutylammonium et d'un solvant non polaire.
CA002186847A 1994-05-10 1995-05-09 Derives adenosine Abandoned CA2186847A1 (fr)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9409324A GB9409324D0 (en) 1994-05-10 1994-05-10 New organic compounds, their preparation and use
GB9409324.2 1994-05-10
US24991494A 1994-05-26 1994-05-26
US249,914 1994-05-26
GB9416693A GB9416693D0 (en) 1994-08-18 1994-08-18 Improvements in or relating to organic compounds
GB9416693.1 1994-08-18

Publications (1)

Publication Number Publication Date
CA2186847A1 true CA2186847A1 (fr) 1995-11-16

Family

ID=27267177

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002186847A Abandoned CA2186847A1 (fr) 1994-05-10 1995-05-09 Derives adenosine

Country Status (13)

Country Link
EP (1) EP0759925A1 (fr)
JP (1) JPH09512823A (fr)
CN (1) CN1147815A (fr)
AU (1) AU2546195A (fr)
BR (1) BR9507683A (fr)
CA (1) CA2186847A1 (fr)
CZ (1) CZ327896A3 (fr)
FI (1) FI964468A0 (fr)
HU (1) HUT75338A (fr)
NO (1) NO964735L (fr)
PL (1) PL316985A1 (fr)
SK (1) SK146096A3 (fr)
WO (1) WO1995030683A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6110902A (en) * 1997-06-23 2000-08-29 Moehler; Hanns Method for the inhibition of neuronal activity leading to a focal epileptic seizure by local delivery of adenosine
GB0228723D0 (en) 2002-12-09 2003-01-15 Cambridge Biotechnology Ltd Treatment of pain
GB0305149D0 (en) * 2003-03-07 2003-04-09 Cambridge Biotechnology Ltd Compounds for the treatment of pain
WO2007107598A1 (fr) 2006-03-21 2007-09-27 Heinrich-Heine-Universität Düsseldorf Agonistes du récepteur a2a phosphorylé
CN108822174A (zh) * 2018-08-29 2018-11-16 上海兆维科技发展有限公司 新型核苷修饰物2’-eoe-鸟嘌呤核苷及其制备方法

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8729994D0 (en) * 1987-12-23 1988-02-03 Glaxo Group Ltd Chemical compounds
GB2226027B (en) * 1988-12-13 1992-05-20 Sandoz Ltd Adenosine derivatives,their production and use
US5017578A (en) * 1989-06-09 1991-05-21 Hoechst-Roussel Pharmaceuticals Inc. N-heteroaryl-purin-6-amines useful as analgesic and anticonvulsant agents
HUT61567A (en) * 1990-12-07 1993-01-28 Sandoz Ag Process for producing new pharmaceutical compositions comprising 2'-o-alkyladenosine derivatives and for producing 6-cyclohexyl-2'-o-methyladenosinehydrate
DK62692D0 (fr) * 1992-05-14 1992-05-14 Novo Nordisk As

Also Published As

Publication number Publication date
HUT75338A (en) 1997-05-28
FI964468L (fi) 1996-11-06
JPH09512823A (ja) 1997-12-22
FI964468A7 (fi) 1996-11-06
BR9507683A (pt) 1997-09-23
PL316985A1 (en) 1997-03-03
HU9603105D0 (en) 1997-01-28
WO1995030683A1 (fr) 1995-11-16
CN1147815A (zh) 1997-04-16
CZ327896A3 (en) 1997-03-12
NO964735L (no) 1997-01-10
NO964735D0 (no) 1996-11-08
AU2546195A (en) 1995-11-29
FI964468A0 (fi) 1996-11-06
SK146096A3 (en) 1997-07-09
EP0759925A1 (fr) 1997-03-05

Similar Documents

Publication Publication Date Title
CA1333390C (fr) Nucleosides fluores et methode de traitement des infections retrovirales avec ces nucleosides
EP0427799B1 (fr) Procede et composes de liberation d'aica-riboside et de reduction du taux de glucose dans le sang
US5658889A (en) Method and compounds for aica riboside delivery and for lowering blood glucose
US4843066A (en) Novel adenosine derivatives and pharmaceutical composition containing them as an active ingredient
EP2298783B1 (fr) Analogues de nucléoside anti-viraux et procédé pour le traitement d'infections virales, en particulier des infections par VIH
CA2163520C (fr) Analogues de l-2',3'-didesoxy nucleoside, agents anti-hepatite b et anti-vih
KR0137786B1 (ko) 심장 또는 뇌의 허혈성 질환의 치료, 예방제
US3502649A (en) N(6) substituted adenosine derivatives
JPH0780898B2 (ja) 抗ウイルスヌクレオシド
JPH07228535A (ja) ウリジンまたはシチジンのアシル誘導体を含有する医薬組成物
WO1998008855A2 (fr) Derives d'adenosine a substitution heterocyclique n6
US5082829A (en) AICA riboside prodrugs
EP0490818A1 (fr) Hydrate de 6-cyclohexyl-2'-0-methyl-adenosine et son utilisations
IL35658A (en) 2, 6 - Diamino - 9 -) B - D - Arbinopuranosil (- Purine, its preparation and use in pharmacy
US3845035A (en) Novel n(6)-substituted adenosine compounds and therapeutic compositions
US4315920A (en) Adenosine deaminase inhibitors
EP0262125A4 (fr) AICA riboside pour le traitement prophylactique de maladies associees à une circulation reduite.
CA2186847A1 (fr) Derives adenosine
JPH0656877A (ja) 抗ウイルス活性および抗ガン活性を有する２’−デオキシ−２’，２’−ジフルオロ（２，６，８−置換）−プリンヌクレオシド類およびその中間体
US5153180A (en) Fluorinated nucleosides and process for treating retrovirus infections therewith
US3966916A (en) N(6)-disubstituted adenoisine compounds and therapeutic compositions
WO2008086341A1 (fr) Procédés, compositions et formulations pour prévenir ou réduire les effets indésirables chez un patient
KR870001935B1 (ko) 항포진성을 갖는 뉴클레오시 유도체 및 그의 산부가염의 제조방법
NZ505531A (en) 7-Propyl-8-oxo-alpha or beta-L-guanine alpha or beta-L-nucleoside
JPS6270387A (ja) ４−アミノ−３−ハロ−２−ピリジノンヌクレオシドおよびヌクレオチド化合物

Legal Events

Date Code Title Description
FZDE Discontinued